Inovio Pharmaceuticals (INO +2.7%) gains at the open after announcing Phase I tests on T cell...

|About: Inovio Pharmaceuticals, Inc. (INO)|By:, SA News Editor

Inovio Pharmaceuticals (INO +2.7%) gains at the open after announcing Phase I tests on T cell and antibody responses were successful in its clinical study of VGX-3400X, a vaccine to prevent avian H5N1 influenza.